Kailera Therapeutics, Inc.
KLRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.42B
Close$
$1.27
92.9% downside
Current Fair Value
92.9% downsideOvervalued by 92.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.42 Billion |
|---|---|
| Enterprise Value | $2.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.26 |
| Beta | 0.5 |
| Outstanding Shares | 117,948,773 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -14.81 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | -4.49 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.91
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 25, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.14%▲ 4.14% |
|---|---|
| Total Invested | $107.62M |
| Investors Holding | 24▲ 24.00% |
ESG Score
No data
About Kailera Therapeutics, Inc.
145 employees
CEO: Ronald C. Renaud Jr. Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tac...